Parag Shah
Keine laufenden Positionen mehr
Vermögen: 1 383 $ am 31.03.2024
Profil
Parag Suresh Shah worked as a Director of Pharmaceutical Science at Ikaria, Inc. and later as a Vice President of Business Operations at Bellerophon Therapeutics, Inc. He received an undergraduate degree from Carnegie Mellon University and a doctorate degree from The University of Texas at Austin.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.10.2023 | 24 705 ( 0,20% ) | 1 383 $ | 31.03.2024 |
Ehemalige bekannte Positionen von Parag Shah
| Unternehmen | Position | Ende |
|---|---|---|
| BELLEROPHON THERAPEUTICS, INC. | Chief Operating Officer | 31.08.2023 |
| IKARIA, INC. | Corporate Officer/Principal | - |
Ausbildung von Parag Shah
| Carnegie Mellon University | Undergraduate Degree |
| The University of Texas at Austin | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BELLEROPHON THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Ikaria, Inc.
 Ikaria, Inc. BiotechnologyHealth Technology Ikaria, Inc. operates as a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to meet the medical needs of critically ill patients. It offers INOMAX for inhalation, which is used to treat newborns suffering from hypoxic respiratory failure, and is making a major impact on the critical care environment. The company was founded on August 18, 2006 and is headquartered in Clinton, NJ. | Health Technology |
